Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 5, 2007, Pages 1032-1034

  Goldenberg, Vanessa K ^a   Seewaldt, Victoria L ^a   Scott, Victoria ^a   Bean, Gregory R ^a   Broadwater, Gloria ^a   Fabian, Carol ^b   Kimler, Bruce ^b   Zalles, Carola ^c   Lipkus, Isaac M ^a,d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c YALE UNIVERSITY MEDICAL CENTER   (United States)

^d Box 34 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TAMOXIFEN;

ADULT; ARTICLE; BREAST AREOLA; BREAST CANCER; CANCER CYTODIAGNOSIS; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DECISION MAKING; DEEP VEIN THROMBOSIS; DRUG USE; ENDOMETRIUM CANCER; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; STROKE; WOMEN'S HEALTH;

ADULT; ANTICARCINOGENIC AGENTS; BIOPSY, FINE-NEEDLE; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; DECISION MAKING; FEMALE; HUMANS; MIDDLE AGED; NIPPLES; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 34250352620     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0910     Document Type: Article

References (24)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
2. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
3. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
4. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Nat Cancer Inst 1999;91: 1829-46.
5. Fabian CJ, Kimler BF. Selective estrogen-receptor modulators for primary prevention of breast cancer. J Clin Oncol 2005;23:1644-55.
6. Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 2004;22:4951-7.
7. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2004; 100:1800-6.
8. McKay A, Latosinsky S, Martin W. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 2005;103:209-10.
9. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001;8: 580-5.
10. Fischer GS, Tulsky JA, Rose MR, Siminoff LA, Arnold RM. Patient knowledge and physician predictions of treatment preferences after discussion of advance directives. J Gen Intern Med 1998;13:447-54.
11. Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod S. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 2005;4:97-103.
12. Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 2005;103:1996-2005.
13. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 2000;92:1217-27.
14. Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer chemoprevention trial of oral α-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 2002;8:3105-17.
15. Bean G, Scott V, Yee L, et al. Methylation of the retinoic acid receptor-β2 in random periareolar fine needle aspiration is an early event in mammary carcinogenesis. Cancer Epidemiol Biomarkers Prev 2005;14:790-813.
16. Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q 1984;11:1-47.
17. Rogers R. Cognitive and physiological processes in fear appeals and attitude change: a revised theory of protective motivation. In: Cacioppo J, Petty R, editors. Social psychophysiology. New York: Guilford Press; 1983. p. 153-76.
18. Weinstein N. The precaution adoption process. Health Psychol 1988;7:355-86.
19. Bastian LA, Lipkus IM, Kuchibhatla MN, et al. Women's interest in chemoprevention for breast cancer. Arch Intern Med 2001;161:1639-44.
20. Meiser B, Butow P, Price M, et al. Attitudes to prophylactic surgery and chemoprevention in Australian women at increased risk for breast cancer. J Womens Health 2003;12:769-78.
21. Zalles C, Kimler B, Kamel S, McKittrick R, Fabian C. Cytology patterns in random aspirates from women at high and low risk for breast cancer. Breast J 1995;1:343-9.
22. Masood S, Frykberg ER, McLellan GL, Scalapino MC, Mitchum DG, Bullard JB. Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions. Cancer 1990;66:1480-7.
23. Masood S, Frykberg ER, McLellan GL, Dee S, Bullard JB. Cytologic differentiation between proliferative and nonproliferative breast disease in mammographically guided fine-needle aspirates. Diagn Cytopathol 1991;7: 581-90.
24. Masood S. Cytomorphology of fibrocystic change, high-risk proliferative breast disease, and premalignant breast lesions. Clin Lab Med 2005;25:713-31.